Clinical trial
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not…
NCT00014209 · NCIC Clinical Trials Group, Other · Completed
Key facts
| NCT number | NCT00014209 |
|---|---|
| Title | Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment |
| Official title | A Phase II Study Of Gemcitabine, Dexamethasone, And Cisplatin (GDP) In Patients With Either Hodgkin's Disease Or Aggressive Histology Non-Hodgkin's Lymphoma Which Is Relapsed Or Refractory |
| Lead sponsor | NCIC Clinical Trials Group, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | cisplatin, dexamethasone, gemcitabine hydrochloride |
| Enrollment | 77 |
| Start date | Dec 12, 2000 |
| Primary completion | Jul 15, 2002 |
| Completion | Feb 10, 2009 |
| First posted | Jul 30, 2003 |
| Last update posted | Apr 9, 2020 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: